OVIDOvid Therapeutics Inc.
$2.34+40% 1Y
$2.34
$1.2052 weeks$2.96
OVID in its own filings
OVID's filing record carries one kind of hard flag, each is shown beside the share of the whole market carrying the same one, because more than half of all companies carry at least one.
205
Events found in the filings · across 532 filings · the record starts in 2017
- Hard flags
- 1
Hard flags
- Most recent filing
- Aug 13, 2026
Most recent filing · Form 10-Q
- Record starts
- Mar 6, 2017
Record starts · the earliest filing Ryufin holds for this name
Details›
- Delisting notice / listing-rule failurepast_3y
- 2025-02-13
- SEC comment-letter activity11 occurrences
- 2026-04-23
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 13, 2026Ovid Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results.Material event (exhibits only) · press release
- Jul 8, 2026Executive Transition On July 5, 2026, Ovid Therapeutics Inc. (the “Company”) and Jeffrey Rona, who served as the Company’s Chief Business and Financial Officer, principal financial officer, principal accounting officer and secretary, mutually agreed to Mr. Rona’s transition from such roles with the Company, effective …Director or officer change · Form 8-K
- Jun 3, 2026On May 29, 2026, the Board of Directors (the “Board”) of Ovid Therapeutics Inc. (the “Company”) approved, effective as of June 15, 2026, an increase in the size of the Board and, upon recommendation of the Nominating and Corporate Governance Committee of the Board (the “Nominating Committee”), the appointment of Anna …Director or officer change · Form 8-K
- May 12, 2026Ovid Therapeutics Reports Business Updates and First Quarter 2026 Financial Results.Material event (exhibits only) · press release
- Apr 20, 2026On April 17, 2026, the Series A Warrants (the “Series A Warrants”) issued by Ovid Therapeutics Inc. (the “Company”) in connection with its October 2025 private placement expired.Other event · Form 8-K
- Mar 18, 2026Securities Purchase Agreement On March 17, 2026, Ovid Therapeutics Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with the purchasers named therein (the “Investors”), pursuant to which the Company agreed to issue and sell an aggregate of 19,154,321 shares (the “Shares”) of …Material agreement entered · Form 8-K
- Dec 18, 2025On December 18, 2025, Ovid Therapeutics Inc. issued a press release announcing results from its Phase 1 study of OV350.Other event · Form 8-K
- Nov 12, 2025On November 11, 2025, the Company’s Board of Directors appointed Margaret “Meg” Alexander, the Company’s President and Chief Operating Officer, as Chief Executive Officer of the Company and as a Class II member of the Company’s Board of Directors (the “Board”), effective January 1, 2026 (the “Effective Date”)Earnings release · Form 8-K
- Oct 3, 2025Securities Purchase Agreement On October 2, 2025, Ovid Therapeutics Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with the purchasers named therein (the “Investors”), pursuant to which the Company agreed to issue and sell an aggregate of (i) 57,722 shares of its Series B …Material agreement entered · Form 8-K
- Sep 16, 2025On September 11, 2025, Ovid Therapeutics Inc., a Delaware corporation (the “Company”), received a formal notification from The Nasdaq Stock Market LLC (“Nasdaq”) confirming that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires listed companies maintain a minimum bid price of at …Other event · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…